Related Experiment Video
Updated: Dec 10, 2025

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
Effect of transfusion convalescent recovery plasma in patients with coronavirus disease 2019
Kun Xiao1, Yang Lin2, Zhifang Fan3
1Department of Blood Transfusion, First Affiliated Hospital of Nanchang University, Nanchang 330006. 376069793@qq.com.
Insights
Convalescent plasma transfusion did not significantly alter outcomes for severe COVID-19 patients. However, it showed potential in neutralizing SARS-CoV-2 and reducing viral load in some individuals.
Area of Science:
- Infectious Diseases
- Hematology
- Critical Care Medicine
Background:
- Severe COVID-19 poses significant clinical challenges.
- Convalescent plasma is explored as a potential therapeutic option for viral infections.
Purpose of the Study:
- To evaluate the curative effects of convalescent plasma transfusion in patients with severe and critical COVID-19.
- To compare clinical outcomes between patients who received convalescent plasma and those who did not.
Main Methods:
- Retrospective analysis of 18 severe/critical COVID-19 patients.
- Comparison of clinical data and prognosis between an experimental group (n=6, plasma transfusion) and an observation group (n=12, no transfusion).
- Analysis of blood oxygen saturation, lymphocyte counts, and SARS-CoV-2 nucleic acid detection in the experimental group post-transfusion.
Main Results:
- No significant differences in basic clinical data or key prognosis indexes (e.g., ventilator weaning, hospitalization days) between groups.
- Blood oxygen saturation remained stable (>90%) in the plasma transfusion group post-transfusion.
- SARS-CoV-2 nucleic acid conversion to negative occurred in 83.3% of patients within 48 hours post-transfusion.
Conclusions:
- Convalescent plasma transfusion did not significantly impact overall outcomes for severe COVID-19 patients in this cohort.
- Transfusion may contribute to neutralizing SARS-CoV-2 and reducing viral load.
- Further research is warranted to elucidate the precise role and optimal use of convalescent plasma in COVID-19 management.
Objectives:
To evaluate curative effects of coronavirus disease 2019 (COVID-19) patients by the transfusion of other convalescent plasma.
Methods:
Retrospective analysis of the clinical data of 18 patients with severe and critical COVID-19, who were hospitalized in the ICU of Xianghu Branch of the First Affiliated Hospital of Nanchang University from February 1 to March 15, 2020. Patients were subdivided into an experimental group (n=6, who had transfused the plasma) and an observation group (n=12, who had no plasma transfusion). Basic clinical data and prognosis indexes of these two groups were compared. Moreover, for the experimental group, the dynamic changes of blood oxygen saturation before and after the transfusion, the changes of lymphocyte absolute value 48 hours after the transfusion, and the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid were analyzed.
Results:
There were no significant differences in age, gender, blood type and other basic clinical data between the two groups (all P>0.05).There were no significant differences in ventilator machine weaning time, extracorporeal membrane oxygenation (ECMO) weaning time, body temperature recovery to normal time, and hospitalization days between these two groups (all P>0.05). For the experimental group, before, during and after the convalescent plasma transfusion, the blood oxygen saturation of all 6 patients at all time (1, 6, 8, 12, 24, 36, and 48 h) was more than 90%, and there was no significant fluctuation. There were 3 patients whose absolute value of lymphocyte was increased 48 hours after the transfusion, and the remaining was decreased. There were 5 patients whose SARS-CoV-2 nucleic acid detection turned negative 48 hours after the transfusion, accounting for 83.3%.
Conclusions:
Transfusion of convalescent plasma will not affect outcomesof COVID-19 patients, which can neutralize SARS-CoV-2 in patients and reduce the loading capacity of SARS-CoV-2.
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-III

